Ruud P M Dings

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1286241/publications.pdf

Version: 2024-02-01

72 papers	4,209 citations	117625 34 h-index	110387 64 g-index
75 all docs	75 docs citations	75 times ranked	5950 citing authors

#	Article	IF	Citations
1	Spectroscopic investigation of radiation-induced reoxygenation in radiation-resistant tumors. Neoplasia, 2021, 23, 49-57.	5.3	7
2	Dendritic cell biocompatibility of etherâ€based urethane films. Journal of Applied Toxicology, 2021, 41, 1456-1466.	2.8	2
3	Dysbiotic stress increases the sensitivity of the tumor vasculature to radiotherapy and c-Met inhibitors. Angiogenesis, 2021, 24, 597-611.	7.2	3
4	Nanoscale investigation and control of photothermal action of gold nanostructure-coated surfaces. Journal of Materials Science, 2021, 56, 10249-10263.	3.7	3
5	Gold nanorods enhance different immune cells and allow for efficient targeting of CD4+ Foxp3+ Tregulatory cells. PLoS ONE, 2021, 16, e0241882.	2.5	3
6	Simulating cellular galectin networks by mixing galectins in vitro reveals synergistic activity. Biochemistry and Biophysics Reports, 2021, 28, 101116.	1.3	2
7	Evidence for Early Stage Anti-Tumor Immunity Elicited by Spatially Fractionated Radiotherapy-Immunotherapy Combinations. Radiation Research, 2020, 194, 688-697.	1.5	29
8	Gastrointestinal Tract Dysbiosis Enhances Distal Tumor Progression through Suppression of Leukocyte Trafficking. Cancer Research, 2019, 79, 5999-6009.	0.9	21
9	Enhanced Photothermal Treatment Efficacy and Normal Tissue Protection via Vascular Targeted Gold Nanocages. Nanotheranostics, 2019, 3, 145-155.	5.2	10
10	Label-Free Raman Spectroscopy Reveals Signatures of Radiation Resistance in the Tumor Microenvironment. Cancer Research, 2019, 79, 2054-2064.	0.9	53
11	Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. International Journal of Radiation Biology, 2019, 95, 436-442.	1.8	77
12	Galectin-1-based tumour-targeting for gold nanostructure-mediated photothermal therapy. International Journal of Hyperthermia, 2018, 34, 19-29.	2.5	16
13	Rapid quantification of mitochondrial fractal dimension in individual cells. Biomedical Optics Express, 2018, 9, 5269.	2.9	9
14	Sample storage conditions induce post-collection biases in microbiome profiles. BMC Microbiology, 2018, 18, 227.	3.3	23
15	Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis, 2018, 21, 425-532.	7.2	429
16	Galectins as Molecular Targets for Therapeutic Intervention. International Journal of Molecular Sciences, 2018, 19, 905.	4.1	83
17	Design of Gold Nanoparticles in Dendritic Cellâ€Based Vaccines. Particle and Particle Systems Characterization, 2018, 35, 1800109.	2.3	13
18	Hypoxia-derived exosomes induce putative altered pathways in biosynthesis and ion regulatory channels in glioblastoma cells. Biochemistry and Biophysics Reports, 2018, 14, 104-113.	1.3	65

#	Article	IF	Citations
19	A Radiosensitizing Inhibitor of HIF-1 alters the Optical Redox State of Human Lung Cancer Cells In Vitro. Scientific Reports, 2018, 8, 8815.	3.3	18
20	Quantitative diffuse reflectance spectroscopy of short-term changes in tumor oxygenation after radiation in a matched model of radiation resistance. Biomedical Optics Express, 2018, 9, 3794.	2.9	15
21	Real-time monitoring of circulating tumor cell (CTC) release after nanodrug or tumor radiotherapy using inÂvivo flow cytometry. Biochemical and Biophysical Research Communications, 2017, 492, 507-512.	2.1	18
22	Triple-negative breast cancer targeting and killing by EpCAM-directed, plasmonically active nanodrug systems. Npj Precision Oncology, 2017, 1, 27.	5.4	34
23	Modifying Dendritic Cell Activation with Plasmonic Nano Vectors. Scientific Reports, 2017, 7, 5513.	3.3	25
24	Optical imaging and spectroscopy of microenvironmental changes associated with radiation resistance in tumors. Proceedings of SPIE, 2017, , .	0.8	0
25	Optical imaging of radiation-induced metabolic changes in radiation-sensitive and resistant cancer cells. Journal of Biomedical Optics, 2017, 22, 060502.	2.6	19
26	Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models. International Journal of Molecular Sciences, 2017, 18, 2671.	4.1	37
27	Quantitative Diffuse Optical Spectroscopy of Short-term Reoxygenation Kinetics in Radiation-Resistant and Sensitive Tumors. , 2017, , .		0
28	Determining the Sensitivity of Diffuse Reflectance Spectroscopy to Dose- and Depth-Dependent Changes in Tumor Oxygenation after Radiation Therapy. , 2017, , .		1
29	Further rationale for optimal combined modality treatments. Oncotarget, 2017, 8, 25831-25832.	1.8	0
30	Targeting Artificial Tumor Stromal Targets for Molecular Imaging of Tumor Vascular Hypoxia. PLoS ONE, 2015, 10, e0135607.	2.5	15
31	Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-Î± and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models. International Journal of Radiation Oncology Biology Physics, 2015, 93, 588-596.	0.8	52
32	Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[18F]fluoroethylazide, and inÂvivo evaluation. European Journal of Medicinal Chemistry, 2015, 89, 279-295.	5.5	38
33	Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Investigational New Drugs, 2013, 31, 1142-1150.	2.6	44
34	Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa. Biochimica Et Biophysica Acta - General Subjects, 2013, 1830, 3454-3457.	2.4	8
35	Structure-Based Optimization of Angiostatic Agent 6DBF7, an Allosteric Antagonist of Galectin-1. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 589-599.	2.5	36
36	Informa-Yamamoto Editorial Award Winners 2011. International Journal of Hyperthermia, 2012, 28, 419-420.	2.5	0

#	Article	IF	Citations
37	Antitumor Agent Calixarene 0118 Targets Human Galectin-1 as an Allosteric Inhibitor of Carbohydrate Binding. Journal of Medicinal Chemistry, 2012, 55, 5121-5129.	6.4	113
38	Microbeam Radiation Therapy Alters Vascular Architecture and Tumor Oxygenation and is Enhanced by a Galectin-1 Targeted Anti-Angiogenic Peptide. Radiation Research, 2012, 177, 804-812.	1.5	54
39	Metformin kills and radiosensitizes cancer cells and preferentially kills cancer stem cells. Scientific Reports, 2012, 2, 362.	3.3	233
40	Synthesis of [¹⁸F]anginex with high specific activity [¹⁸F]fluorobenzaldehyde for targeting angiogenic activity in solid tumors. Journal of Labelled Compounds and Radiopharmaceuticals, 2011, 54, 708-713.	1.0	3
41	Enhancement of T-cellâ€“Mediated Antitumor Response: Angiostatic Adjuvant to Immunotherapy against Cancer. Clinical Cancer Research, 2011, 17, 3134-3145.	7.0	64
42	Tumour thermotolerance, a physiological phenomenon involving vessel normalisation. International Journal of Hyperthermia, 2011, 27, 42-52.	2.5	24
43	Inhibiting Tumor Growth by Targeting Tumor Vasculature with Galectin-1 Antagonist Anginex Conjugated to the Cytotoxic Acylfulvene, 6-Hydroxylpropylacylfulvene. Bioconjugate Chemistry, 2010, 21, 20-27.	3.6	40
44	Mild temperature hyperthermia and radiation therapy: Role of tumour vascular thermotolerance and relevant physiological factors. International Journal of Hyperthermia, 2010, 26, 256-263.	2.5	65
45	Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCFâ€7 breast cancer xenografts and carcinogenâ€induced mammary tumors in rats. International Journal of Cancer, 2008, 123, 1196-1204.	5.1	42
46	Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Letters, 2008, 265, 270-280.	7.2	48
47	Probing structureâ€“activity relationships in bactericidal peptide Î²pep-25. Biochemical Journal, 2008, 414, 143-150.	3.7	8
48	Non-Peptidic Mimetics as Cancer-Sensitizing Agents. , 2008, , 305-325.		1
49	Scheduling of Radiation with Angiogenesis Inhibitors Anginex and Avastin Improves Therapeutic Outcome via Vessel Normalization. Clinical Cancer Research, 2007, 13, 3395-3402.	7.0	270
50	Modulation of Angiogenic Phenotype Alters Tumorigenicity in Rat Ovarian Epithelial Cells. Cancer Research, 2007, 67, 3683-3690.	0.9	36
51	A Journey in Structure-Based Drug Discovery: From Designed Peptides to Protein Surface Topomimetics as Antibiotic and Antiangiogenic Agents. Accounts of Chemical Research, 2007, 40, 1057-1065.	15.6	39
52	Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay. International Journal of Clinical Oncology, 2007, 12, 42-47.	2.2	33
53	Topomimetics of Amphipathic Î²-Sheet and Helix-Forming Bactericidal Peptides Neutralize Lipopolysaccharide Endotoxins. Journal of Medicinal Chemistry, 2006, 49, 7754-7765.	6.4	56
54	Design of Nonpeptidic Topomimetics of Antiangiogenic Proteins With Antitumor Activities. Journal of the National Cancer Institute, 2006, 98, 932-936.	6.3	102

#	Article	IF	Citations
55	Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochemical and Biophysical Research Communications, 2006, 349, 1073-1078.	2.1	28
56	Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood, 2006, 108, 2339-2348.	1.4	226
57	Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications. Cancer Research, 2006, 66, 10770-10777.	0.9	139
58	Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15975-15980.	7.1	424
59	Antiâ€angiogenesis therapy can overcome endothelial cell anergy and promote leukocyteâ€endothelium interactions and infiltration in tumors. FASEB Journal, 2006, 20, 621-630.	0.5	237
60	Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. International Journal of Cancer, 2005, 115, 312-319.	5.1	81
61	Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochemical and Biophysical Research Communications, 2005, 333, 1261-1268.	2.1	25
62	VEGFâ€”DT385 Toxin Conjugate Inhibits Mammary Adenocarcinoma Development in a Transgenic Mouse Model of Spontaneous Tumorigenesis. Breast Cancer Research and Treatment, 2004, 85, 161-171.	2.5	11
63	Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. International Journal of Cancer, 2004, 110, 343-351.	5.1	53
64	Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Experimental Cell Research, 2004, 299, 286-293.	2.6	76
65	Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis, 2003, 6, 83-91.	7.2	23
66	Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Letters, 2003, 194, 55-66.	7.2	65
67	Design of a Partial Peptide Mimetic of Anginex with Antiangiogenic and Anticancer Activity. Journal of Biological Chemistry, 2003, 278, 45746-45752.	3.4	62
68	beta-Sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochemical Journal, 2003, 373, 281-288.	3.7	51
69	The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Research, 2003, 63, 382-5.	0.9	85
70	The designer antiangiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB Journal, 2002, 16, 1991-1993.	0.5	96
71	Tumor angiogenesis factors reduce leukocyte adhesion in vivo. International Immunology, 2000, 12, 671-676.	4.0	61
72	Understanding Galectin Structureâ€“Function Relationships to Design Effective Antagonists. , 0, , 33-69.		15